The DANISH study (Danish Study to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients With NonIschemic Systolic Heart Failure on Mortality) did not demonstrate an overall effect on all-cause mortality with ICD implantation. However, the prespecified subgroup analysis suggested a possible age-dependent association between ICD implantation and mortality with survival benefit seen only in the youngest patients. The nature of this relationship between age and outcome of a primary prevention ICD in patients with nonischemic systolic heart failure warrants further investigation.
P
atients with systolic heart failure are at increased risk of sudden cardiac death (SCD). 1 An implantable cardioverter-defibrillator (ICD) significantly reduces this risk in patients with systolic heart failure caused by ischemic heart disease. 2 However, no single study based exclusively on patients with systolic heart failure not caused by coronary artery disease has demonstrated a mortality reduction with ICD implantation. The recent DANISH study (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality) found no reduction in allcause mortality when patients with nonischemic systolic heart failure were treated with an ICD. 3 However, the association of ICD implantation with survival was significantly different depending on age, with lower all-cause mortality in the 2 youngest tertiles combined but not in the older tertile. Although a possible age-dependent relationship of ICDs with survival is a relevant clinical question, few data on this exist.
The majority of deaths in patients with chronic systolic heart failure result from cardiovascular causes, mainly fatal arrhythmias or worsening of heart failure, but a substantial number of patients also die of noncardiovascular causes. 4 An ICD can prevent SCD caused only by ventricular tachyarrhythmia, severe bradycardia, or complete heart block; it cannot provide protection against other causes of death. 5 The causes of death in patients with heart failure change with age. 6 Younger patients may be more prone to ventricular tachyarrhythmia, whereas older patients may be more likely to die of pump failure or noncardiovascular reasons. 4 The purpose of the present analysis is to provide further insight into the relationship between ICD implantation and all-cause mortality and SCD by age.
METHODS

The DANISH Study
The detailed design of the DANISH trial was reported previously. 7 In brief, DANISH was a randomized controlled trial addressing ICD implantation in patients with nonischemic systolic heart failure. 3 In total, 1116 patients with documented nonischemic systolic heart failure with left ventricular ejection fraction ≤35% and increased levels (>200 pg/ mL) of NT-proBNP (N-terminal pro-brain natriuretic peptide) were randomized to ICD or control. Exclusion of ischemic heart disease as the cause of heart failure was done by coronary angiography (96% of patients), computed tomography angiography, or nuclear myocardial perfusion imaging. Patients were primarily in New York Heart Association functional class II or III. New York Heart Association class IV was accepted in candidates for cardiac resynchronization therapy (CRT). Patients with preexisting conventional pacemaker or CRT-pacemaker could be included. Patients with permanent atrial fibrillation and a resting heart rate >100 bpm and patients with end-stage renal failure (dialysis) were excluded.
Ethics
The study was performed according to the principles of the Declaration of Helsinki. Patients were enrolled only after providing informed consent. The study was approved by the regional scientific ethics committee for the capital region (H-D-2007-0101) and the Danish Data Protection Agency. In addition, the trial is registered at ClinicalTrials.gov with the identifier NCT00542945.
Age Groups and Causes of Death
Age was the only prespecified subgroup with a significant treatment-by-subgroup interaction in the DANISH trial (P=0.009 for interaction with age divided into tertiles). Age tertiles based on age at randomization were used for initial demographic analysis according to the prespecified analysis plan: age group 1, <59 years; age group 2, 59 to <68 years; and age group 3, ≥68 years.
The primary end point, death resulting from any cause, and the secondary end points of cardiovascular death, SCD, and noncardiac death were adjudicated according to previously reported criteria by a clinical end-point committee. 7 Cardiovascular deaths were subclassified as sudden or nonsudden. SCD was defined as death occurring unexpectedly in a previously stable patient, death occurring within an hour of onset or worsening of symptoms, or unwitnessed death, when patients were last seen alive <72 hours before death with no sign of life-threatening disease or symptoms, and when circumstances suggested sudden death such as when
Clinical Perspective
What Is New?
• In the present study, we explored further the association between implantable cardioverter-defibrillator (ICD) and all-cause mortality by age in the DANISH study (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality). We found a mortality reduction in association with an ICD in the younger part of the population only, and data from this study suggest an age cutoff of 70 years.
• Modes of death differ according to age, and younger patients more often experience sudden cardiac death, which is why an ICD was found to be associated with improved survival rates.
What Are the Clinical Implications?
• ICDs were associated with reduced all-cause mortality only in the younger part of the population of patients with nonischemic systolic heart failure.
• Younger patients seem to benefit more from an ICD than older patients, primarily because sudden cardiac death accounts for a higher proportion of death in the younger patients.
the patient was found in bed. Noncardiovascular deaths were defined as all deaths not adjudicated as cardiovascular death. Cardiovascular deaths classified as nonsudden and all noncardiovascular deaths were categorized together as nonsudden deaths.
Statistical Analysis
Baseline characteristics of the age groups were compared with the χ 2 test for categorical variables and Kruskal-Wallis test for continuous variables. Outcomes were analyzed with the use of time-to-event methods. All analyses were performed in the intention-to-treat population. The relationship between ICD and survival by age was assessed with linear and spline-based models for effects on the log hazard of death, with separate effects of age estimated in each treatment group. The model with the lowest Akaike information criterion was selected as having the best balance between fit and parsimony. 8, 9 In addition, a selection impact analysis was performed, describing the expected survival in the full population under different age-based thresholds for ICD treatment assignment. 10, 11 The selection impact estimate is nonparametric because each time point represents a weighed combination of Kaplan-Meier estimates from the relevant treatment groups. Thus, the overall survival for the population, including both the patients who received an ICD and those who did not, is estimated. For example, the estimated effect of assigning patients ≤50 years of age to ICD is the weighted average of the Kaplan-Meier estimates for survival in the ICD arm for patients ≤50 years of age and in the control arm for patients >50 years of age, with the average weighed by the proportions of patients in the corresponding age groups. Ninety-five percent confidence intervals (CIs) were estimated with bootstrapping. Cumulative incidence curves were calculated for all-cause mortality and for cardiovascular death, SCD, and nonsudden death, taking competing risks into account. Formal assessment of proportional hazard did not find significant nonproportionality (P=0.23). Differences in the distribution of mode of death between age groups were assessed with frequency tables and the χ 2 test. Incidences rates were estimated by Poisson regression and are expressed as events per 100 patient-years. In a multivariable Cox regression model, we tested the interaction between age and treatment strategy, controlling for known risk factors. Two-sided values of P<0.05 were considered statistically significant. All analyses were performed with SAS software version 9.4 (SAS Institute) and R software version 3.3.1 (R Project for Statistical Computing).
RESULTS
Baseline characteristics for the age tertiles are presented in the Table. Median age of the study population was 63 years (range, 21-84 years; Figure 1 ). The oldest age group had a significantly higher prevalence of comorbidities, a longer duration of heart failure, and an adverse biomarker profile (NT-proBNP and lower renal function [estimated glomerular filtration rate]), and slightly fewer received target doses of guideline therapy. The median follow-up time for the entire population was 67.6 months, with no difference between groups. Baseline characteristics for patients according to age tertiles and randomization for those ≤68 and >68 years and ≤70 and >70 years of age are presented in Tables I  through III in the online-only Data Supplement. Figure 2 shows the relation between age and risk of all-cause mortality comparing ICD treatment and control. Increasing the model complexity beyond a linear relationship with age did not sufficiently improve model fit to justify the additional model complexity. Each year of younger age was associated with a 3.0% (95% CI, 0.03-6.0; P=0.03) further reduction in the hazard ratio (HR) for the benefit of an ICD, and the point estimate crossed 1.0 at just after 70 years of age.
The selection impact curve is presented in Figure 3 . Each point on the curve shows the estimated total 7-year survival for the population in case this specific age was chosen as the cutoff for ICD treatment. The 7-year survival rate in the overall population is estimated at 70% if no one received an ICD and at 72% if everyone received an ICD. The maximum survival rate of the entire population was estimated with a cutoff of ≤70 years for ICD implantation, with 75% surviving. A cutoff at ≤70 years was therefore used for further analysis of modes of death. A selection impact analysis with 1-year age intervals, depicting age ≤70 years as the highest age cutoff with significant survival benefit for the entire population, is shown in Figure I in the online-only Data Supplement.
In Figure 4 , the time-to-event curves for all-cause mortality are stratified by the cutoff of ≤70 years. Patients ≤70 years of age had significantly better survival when treated with an ICD (HR, 0.70; 95% CI, 0.51-0.96; P=0.03). After 7 years of follow-up, patients with an ICD had 8% lower absolute mortality (1.1%/y). For patients >70 years old, ICD implantation was not associated with improved all-cause mortality (HR, 1.05; 95% CI, 0.68-1.62; P=0.84). In a multivariable model adjusted for sex, CRT, body mass index, NT-proBNP, estimated glomerular filtration rate, New York Heart Association class, duration of heart failure, hypertension, diabetes mellitus, atrial fibrillation, and use of β-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and mineralocorticoid-receptor antagonist, ICD was significantly associated with improved survival (P=0.02) for patients <70 years of age. Figure 5 shows the cumulative rates of SCD and nonsudden death in the control group only. Among patients ≤70 years of age randomized to the control group, the incidence rate of SCD was 1.8 (95% CI, 1.3-2.5) and for nonsudden death was 2.7 (95% CI, 2.1-3.5) events per 100 patient-years. In contrast, for patients >70 years of age, the incidence rate for SCD was 1.6 (95% CI, 0.8-3.2) and for nonsudden death was 5.4 (95% CI, 3.7-7.8) events per 100 patient years.
ORIGINAL RESEARCH ARTICLE
This difference in distribution of mode of death was statistically significant (P=0.01). The corresponding cumulative rates of SCD and nonsudden death for patients randomized to ICD treatment are presented in Figure 6 . Figures II and III in the online-only Data Supplement show the risk of SCD and nonsudden death, respectively, according treatment with ICD or control for patients ≤70 and >70 years of age.
A successful ICD shock was experienced by 46 patients <70 years of age and 10 patients >70 years of age. The cumulative incidence of first successful ICD shock after 7 years of follow-up was 0.72% (95% CI, 0.66-0.78) for patients <70 years of age compared with 0.48% (95% CI, 0.39-0.61) for patients >70 years of age.
All results reported with age ≤70 years as the cutoff were similar if age ≤68 years was used instead with no changes in statistical significance.
DISCUSSION
In this study in patients with nonischemic systolic heart failure, the association between the ICD and all-cause mortality decreased with advancing age in a linear re- Preexisting pacemaker or CRT-pacemaker, n (%) 20 (6) 30 (8) 52 (13) 0.001 ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid-receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; and NYHA, New York Heart Association. lation, and no association between the ICD and survival was observed in older patients. Modes of death vary with age, and although sudden death rates were roughly similar between younger and older patients, the rate of nonsudden death was twice as high in the older population.
Limited data exist on the relation between the ICD and all-cause mortality by age. A previous metaanalysis found a survival benefit of ICD implantation for all patients, but with benefit decreasing with increasing age. 12 In the current international guidelines, implantation of an ICD is recommended for patients with systolic heart failure regardless of pathogenesis and age. 13, 14 Meta-analyses of all trials of patients with nonischemic systolic heart failure, including the results of the DANISH study, found a significant reduction in all-cause mortality for the entire population. 15, 16 However, the result from our study suggests that ICD implantation in patients with nonischemic systolic heart failure significantly decreases all-cause mortality only in the younger patients. This is in accordance with a meta-analysis of the MADIT II trial (Multicenter Au- Shown is the linear relationship between age and survival of patients by ICD implantation. The x axis shows age in years; the y axis, hazard ratios (HRs). Dashed gray horizontal line indicates HR=1, which corresponds to an equal mortality in patients treated with an ICD and control. The full black line illustrates risk for all-cause mortality according to age, and dashed gray lines show the 95% confidence interval.
tomatic Defibrillator Implantation II), SCD-HeFT trial (Sudden Cardiac Death in Heart Failure), and DEFINITE trial (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation), which showed that age may be associated with the benefit of an ICD with a smaller reduction in all-cause mortality in older compared with younger patients. 17 For an ICD to prevent death, the underlying cause must be arrhythmic. Therefore, the potential benefit of ICD implantation depends on a patient's risk of SCD relative to the risk of nonsudden death. Correspondingly, we found no association between ICD and nonsudden death regardless of age. The potential benefit of ICD implantation therefore depends on a patient's risk of SCD relative to the risk of nonsudden death. In the present study, we investigated the modes of death in patients not treated with an ICD. Older patients were twice as likely as younger patients to die of causes other than SCD, and consequently, SCD accounted for a higher proportion of deaths among the younger patients than the older patients. This pattern was also seen in an analysis of >6000 patients with structural heart disease, primarily heart failure caused by coronary artery disease, in which death resulting from any cause increased with age whereas the incidence of SCD decreased. 6 All this may explain why ICD implantation has less impact in older patients. A dichotomous age cutoff for effect of an ICD will be arbitrary, but our analyses suggest an optimal cutoff of ≤70 years of age in the population randomized in the DANISH study. However, because other factors may also be of importance when ICD implantation is considered, a rigid age cutoff should not be stated. Overall, the mortality rates in DANISH were lower than in previous studies addressing ICD implantation. 18, 19 Figure 3. Selection impact curve to describe the expected survival in the full population under different age-based thresholds for implantable cardioverterdefibrillator (ICD) treatment assignment. Each point (black circle) shows the total 7-year survival in the population if this age is chosen as cutoff for ICD treatment. Gray vertical lines show the 95% confidence interval. The estimate is nonparametric because each point on the curve is a weighted combination of Kaplan-Meier estimates from the relevant treatment groups. The survival in the entire population is 75% when ICD implementation is restricted to patients ≤70 years of age. The graph does not show survival rates for patients with the specified ages along the horizontal axis but rather the survival rate in the entire population when ICD use is assigned on the basis of the different age thresholds. Many factors are important in the consideration of ICD implantation. First, patients' preferences should be taken into account. Studies have shown that patients with heart failure express different preferences concerning treatment strategy according to age. Younger patients often emphasize longer life expectancy and prefer increased survival time, whereas older patients consider quality of life of greater importance. 20 Second, balance between the potential benefits and risks of ICD implantation is important. ICD implantation is an invasive procedure with risk of perioperative complications such as pneumothorax, bleeding, and cardiac perforation, and late complications associated with ICD treatment such as inappropriate shocks, devicerelated infection, the fear of appropriate shocks, and quality of life are to be considered. 21 Consequently, risk stratification techniques are needed to adequately optimize the risk/benefit balance of ICD implantation in individual patients. 22 In this study, the patients in the oldest age group presented worse on almost all clinical parameters. A worse risk factor profile might be associated with modes of death and outcomes of an ICD and should be taken into account before ICD implantation.
Limitations
In the present analysis, the bulk of patients were between 40 and 80 years old, with very few patients outside this range. Consequently, conclusions outside this age span are based on extrapolations. We found the highest survival for the entire population with ICD implantation in patients ≤70 years of age, but confidence limits of the estimate were wide, and we cannot conclude that age ≤70 years is significantly superior to any other age cutoff. As in any clinical trial, patient selection may be an issue, and selection bias might be more pronounced with age. Consequently, 68% of patients >70 years of age who were included in DANISH were scheduled for CRT, and this might have affected our results. In addition, this is a subgroup analysis, and randomization to ICD or control was not stratified by age. Randomization was not blinded because of the surgical procedure, and this may have influenced the clinical treatment strategy afterward. CRT was implanted in 58% of the patients (and in 68% of patients >70 years of age), which may have influenced our findings. The inclusion criteria of NTproBNP did not change according to age, which might have influenced the risk and severity of heart disease in the older population and thereby also modes of death.
All this must be borne in mind in the interpretation of our results and before they are applied in clinical practice.
Conclusions
In this post hoc analysis of the DANISH study, ICD implantation was associated with reduced all-cause mor- Circulation is available at http://circ.ahajournals.org.
